Allena Pharmaceuticals, Inc.

OTCPK:ALNA.Q Stock Report

Market Cap: US$109.9k

Allena Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Allena Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 17.4% annually.

Key information

-12.94%

Earnings growth rate

61.80%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-1,157.52%
Net Marginn/a
Last Earnings Update30 Jun 2022

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jul 19

First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment

Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout patients with stage 2 and stage 3 chronic kidney disease (CKD). ALNA is planning to enroll up to four cohorts in the mid-stage trial, called Study 202, with each cohort consisting of up to 12 patients. Cohort A of the trial has enrolled seven patients with stage 2, or mild CKD, and cohort B has enrolled 12 patients with stage 3, or moderate CKD. ALNA said safety and efficacy data from the first two cohorts of the study are expected to be available later this quarter. ALNA stock +1.5% to $0.15 in morning trading.
Seeking Alpha • Jul 05

Allena Pharma reschedules special meeting to approve reverse stock split, shares fall

Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had rescheduled its special meeting to consider and approve a reverse stock split of its common shares. ALNA stock has lost 16.5% to $0.18 in morning trading. The special meeting had been scheduled for today. ALNA did not give any reasons for the rescheduling decision. According to Seeking Alpha data, ALNA had 114.53M shares outstanding.
Seeking Alpha • Jan 08

Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days

Allena Pharmaceuticals is trading below 10% of analyst price targets. Analysts have not adjusted these price targets down, despite their presence at the January 4 webinar or conference call. Allena Pharmaceuticals must identify a partner, secure a buyout, or arrange for financing in the next 90 days or they will not survive. They, also, face NASDAQ de-listing in February 2022, if they cannot get the price-per-share of their stock above $1 and sustain this price-per-share. I like these “beaten up” stocks for a “nibble” – there really is no bad news left and I cannot believe that they will not get a deal done in the first quarter of 2022. I recommend a very small purchase of Allena Pharmaceuticals stock at or below $0.60 per share in anticipation of a buyout, partnering or financing in the next 90 days.
Analysis Article • Dec 29

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...

Revenue & Expenses Breakdown

How Allena Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:ALNA.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 220-431229
31 Mar 220-491335
31 Dec 210-491335
30 Sep 210-491434
30 Jun 210-441330
31 Mar 210-371224
31 Dec 200-331220
30 Sep 200-341122
30 Jun 200-391028
31 Mar 200-441033
31 Dec 190-471037
30 Sep 190-461036
30 Jun 190-421032
31 Mar 190-391030
31 Dec 180-36926
30 Sep 180-33924
30 Jun 180-28820
31 Mar 180-24617
31 Dec 170-22516
30 Sep 170-21516
30 Jun 170-23418
31 Mar 170-24419
31 Dec 160-25420

Quality Earnings: ALNA.Q is currently unprofitable.

Growing Profit Margin: ALNA.Q is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ALNA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.

Accelerating Growth: Unable to compare ALNA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Return on Equity

High ROE: ALNA.Q has a negative Return on Equity (-1157.52%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/30 14:08
End of Day Share Price 2023/05/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allena Pharmaceuticals, Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Madhu KumarB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.